CLINICAL TRIALS PROFILE FOR VANCOCIN HYDROCHLORIDE
✉ Email this page to a colleague
▶ Start for $1
Remove trial restrictions
All Clinical Trials for Vancocin Hydrochloride
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00384527 ↗ | Study of Nitazoxanide in the Treatment of Clostridium Difficile-associated Disease | Terminated | Romark Laboratories L.C. | Phase 3 | 2006-12-01 | The primary objective of the study is to demonstrate non-inferiority of nitazoxanide compared to vancomycin in resolving symptoms of Clostridium difficile-associated disease (CDAD). |
| NCT00428844 ↗ | Study of Daptomycin in Subjects Undergoing Surgery for Osteomyelitis Associated With an Infected Prosthetic Caused by Staphylococci | Completed | Cubist Pharmaceuticals LLC | Phase 2 | 2007-06-26 | This is a research study designed to look at the efficacy and safety of daptomycin given at a dose of 6 mg/kg or 8 mg/kg in subjects being treated for prosthetic hip or knee infections caused by Staphylococci. These types of bacteria are among the most common types of bacteria causing infections of prosthetic joints. |
| NCT00430937 ↗ | Efficacy and Safety of Daptomycin Versus Vancomycin or Teicoplanin for Treatment of Complicated Skin and Soft Tissue Infections | Terminated | Novartis Pharmaceuticals | Phase 3 | 2006-04-01 | This study evaluated the efficacy and safety of daptomycin compared to vancomycin or teicoplanin for the treatment of complicated skin and soft tissue infections |
| NCT00695903 ↗ | Phase 2 Study of Safety, Efficacy, and Pharmacokinetics of Higher Doses of Daptomycin and Vancomycin in MRSA Bacteremia | Terminated | Cubist Pharmaceuticals LLC | Phase 2 | 2008-09-17 | The overall goals of this study are to compare the safety and efficacy of daptomycin monotherapy 10 mg/kg/day and vancomycin monotherapy dosed to achieve vancomycin trough levels of 15 to 20 μg/mL for the treatment of methicillin-resistant S. aureus bacteremia (MRSA), including right-sided infective endocarditis (RIE). |
| NCT01198509 ↗ | Role of Oral and Intestinal Microbiota in Rheumatoid Arthritis (RA) | Completed | Memorial Sloan Kettering Cancer Center | N/A | 2010-01-01 | Rheumatoid arthritis (RA) is an inflammatory form of arthritis that causes joint pain and damage. RA attacks the lining of the joints (synovium), causing swelling that can result in aching and throbbing, and eventually deformity. Even though there have been many advances in the treatment of RA, psoriatic arthritis (PsA), and other inflammatory arthritis, doctors still do not know what causes this inflammation in joints. It is likely that RA occurs as a result of a complex combination of factors, including a person's genes; lifestyle choices, such as smoking and diet; and things in a person's environment, including bacteria or viruses. This study investigates the hypothesis that bacteria living in a person's mouth and/or intestinal tract are responsible, at least in part, for the development of Rheumatoid Arthritis. The investigators believe that by killing those bacteria with antibiotics, they might be able to understand how the immune system works and, maybe, what causes RA. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for Vancocin Hydrochloride
Condition Name
Clinical Trial Locations for Vancocin Hydrochloride
Trials by Country
Clinical Trial Progress for Vancocin Hydrochloride
Clinical Trial Phase
Clinical Trial Sponsors for Vancocin Hydrochloride
Sponsor Name
